Comprehensive Tumor Panel (320 Genes) – NGS Genomic Profiling in UAE

Executive Summary & Core Metrics

Accuracy Guarantee:
99.9% diagnostic sensitivity via ISO 9001:2015 accredited NGS processing, validated against AMP/ACMG 2025 standards.

Logistics:
Secure Medical Courier Solid Tissue Specimen Retrieval – hospital extraction only; mobile home phlebotomy disabled for safety.

Clinical Guidance:
Post-test telephonic consultation with a DHA-licensed specialist to interpret actionable mutations and guide therapy decisions.

Insurance:
Direct billing verification via WhatsApp +971 54 548 8731 – pre-approval within 60 minutes.

Test Overview & Methodology

This next-generation sequencing (NGS) panel interrogates 320 cancer-related genes across all major solid tumors and hematologic malignancies, providing a comprehensive genomic profile for diagnosis, prognosis, and targeted therapy selection. The assay detects single nucleotide variants (SNVs), insertions/deletions (indels), copy number variations (CNVs), and gene fusions with high sensitivity and specificity.

Feature	Our Test	Closest Alternative
Precision	99.9% sensitivity – capture of SNVs, indels, CNVs, fusions (NovaSeq 6000, >1000x unique depth)	Smaller panels (50–100 genes) or single-gene tests may miss rare driver mutations
Method	NGS with full exon coverage + hotspot regions, TMB & MSI status included	PCR-based hotspot testing or FISH for a few genes only
Turnaround	21 Working Days (expedited available)	Often 4–6 weeks

Physician Insight & Safety Protocols

“As a DHA-licensed specialist in diagnostic radiology with expertise in oncologic imaging, I emphasize that a 320-gene panel provides comprehensive genomic context crucial for precision oncology. The results must be integrated with histopathology and radiological staging to guide targeted therapies, immunotherapy, or clinical trial eligibility. I urge all patients to discuss findings with their treating oncologist before making any treatment changes.”

— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011

⚠️ Medication Safety Advisory

Do not discontinue or adjust any prescribed medication or treatment regimen based solely on this genomic test result. Always consult your treating oncologist or specialist before implementing any therapeutic changes.

Exclusion Criteria & ER Red Flags

Sample Rejection: Insufficient tumor content (<20% nuclei), improper formalin fixation >48 hours, decalcified specimens, or degraded DNA.
Emergency Red Flags: If you experience acute symptoms (unrelenting pain, sudden neurological changes, severe hemorrhage), seek emergency care immediately — do not wait for genomic results.
Pediatric Cases: In compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability, minors require a guardian's informed consent and presence during sample collection.

Patient FAQ & Clinical Guidance

1. What does the Comprehensive Tumor Panel (320 Genes) actually detect?

The panel identifies mutations, copy number changes, and gene fusions across 320 clinically relevant cancer genes — delivering a precise genomic blueprint that oncologists use to match targeted therapies, predict prognosis, and uncover hereditary risk syndromes. The analysis covers both somatic and germline variants with high confidence.

2. How long does it take to receive results and how are they reported?

Results are delivered within 21 working days as a secure, DHA-compliant PDF that includes an interpretative summary, clinically actionable tier classification, and direct phone consultation with our molecular oncology specialist to walk you through every finding. Expedited reporting is available upon request.

3. Is the test covered by UAE insurance and how is the sample collected?

Insurance coverage varies by plan; we offer direct billing verification through WhatsApp +971 54 548 8731 (60-minute response). Sample collection is a hospital-only procedure: your surgeon or oncologist provides the FFPE tumor tissue block or slides. Our medical courier retrieves the specimen under strict temperature control. Mobile home phlebotomy is not available for this test due to the requirement for invasive tissue sampling.

UAE Regulatory & Data Privacy Adherence

Compliance Framework

This laboratory service strictly adheres to:

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Federal Decree-Law No. 4 of 2016 on Medical Liability for clinical safety and patient consent.
ISO 9001:2015 Certification (Cert: INT/EGQ/2509DA/3139).

All genomic findings are reported by DHA-licensed professionals and processed in our Dubai Healthcare City facility.

Clinical & Logistical Metadata

Test Name	Comprehensive Tumor Panel (320 Genes) – NGS Genomic Profiling
Price (AED)	4,000 AED
Turnaround Time	21 Working Days
Sample Type / Matrix	Archival Tumor Tissue (FFPE Block or Slides) – Hospital Extraction Only
Methodology Used	Next-Generation Sequencing (NGS) – Full exon coverage, TMB & MSI analysis
ICD-10-CM Code	Z12.9, Z12.0
LOINC Code	92854-5
DHA Facility License & Address	License #1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE